Progyny, Inc. PGNY
We take great care to ensure that the data presented and summarized in this overview for Progyny, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PGNY
View all-
Black Rock Inc. New York, NY11.8MShares$272 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.62MShares$198 Million0.0% of portfolio
-
Thrivent Financial For Lutherans Minneapolis, MN3.4MShares$78.1 Million0.27% of portfolio
-
State Street Corp Boston, MA2.91MShares$67 Million0.0% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO2.21MShares$50.8 Million0.9% of portfolio
-
Geode Capital Management, LLC Boston, MA1.8MShares$41.4 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.56MShares$35.9 Million0.03% of portfolio
-
Marshall Wace, LLP London, X01.48MShares$34 Million0.04% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.45MShares$33.4 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.3MShares$29.9 Million0.02% of portfolio
Latest Institutional Activity in PGNY
Top Purchases
Top Sells
About PGNY
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Insider Transactions at PGNY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2025
|
David J Schlanger Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
1,893
-0.84%
|
$41,646
$22.0 P/Share
|
|
Jul 01
2025
|
Peter Anevski CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
7,977
-1.44%
|
$175,494
$22.0 P/Share
|
|
Jun 11
2025
|
Cheryl Scott Director |
SELL
Open market or private sale
|
Direct |
2,675
-15.93%
|
$58,850
$22.07 P/Share
|
|
Jun 04
2025
|
Allison Swartz EVP, GC |
SELL
Payment of exercise price or tax liability
|
Direct |
339
-0.41%
|
$7,119
$21.98 P/Share
|
|
Jun 04
2025
|
Mark S. Livingston CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
339
-0.47%
|
$7,119
$21.98 P/Share
|
|
Jun 04
2025
|
Michael E Sturmer PRESIDENT |
SELL
Payment of exercise price or tax liability
|
Direct |
7,977
-2.55%
|
$167,517
$21.98 P/Share
|
|
Jun 02
2025
|
Michael E Sturmer PRESIDENT |
SELL
Payment of exercise price or tax liability
|
Direct |
448
-0.14%
|
$9,408
$21.5 P/Share
|
|
Jun 02
2025
|
Mark S. Livingston CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,848
-2.49%
|
$38,808
$21.5 P/Share
|
|
May 28
2025
|
Allison Swartz EVP, GC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,352
-1.61%
|
$27,040
$20.59 P/Share
|
|
May 22
2025
|
Cheryl Scott Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+28.49%
|
-
|
|
May 22
2025
|
Kevin K Gordon Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,026
+37.86%
|
-
|
|
May 22
2025
|
Jeffrey G Park Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,364
+22.61%
|
-
|
|
May 22
2025
|
Lloyd H Dean Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,026
+28.92%
|
-
|
|
May 22
2025
|
Roger C Holstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,026
+26.79%
|
-
|
|
May 22
2025
|
Norman Payson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+24.4%
|
-
|
|
Apr 14
2025
|
Melissa B Cummings Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,667
+50.0%
|
-
|
|
Apr 01
2025
|
Peter Anevski CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
7,977
-1.42%
|
$175,494
$22.34 P/Share
|
|
Apr 01
2025
|
David J Schlanger Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
1,893
-0.84%
|
$41,646
$22.34 P/Share
|
|
Mar 04
2025
|
Allison Swartz EVP, GC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,417
-1.66%
|
$31,174
$22.0 P/Share
|
|
Mar 04
2025
|
Mark S. Livingston CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,350
-1.78%
|
$29,700
$22.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 275K shares |
|---|---|
| Open market or private purchase | 360K shares |
| Open market or private sale | 2.88K shares |
|---|---|
| Payment of exercise price or tax liability | 115K shares |